SUPT20HL1: A Drug Target / Disease Biomarker (G100130302)

Target Name: SUPT20HL1

NCBI ID: G100130302

SUPT20HL1: A Drug Target / Disease Biomarker

SUPT20HL1 is a drug target and a potential biomarker for the treatment of various diseases, including cancer. The protein is located on the surface of certain immune cells, including natural killer cells, and is involved in the immune response.

Research has shown thatSUPT20HL1 is a promising target for cancer treatment because it is overexpressed in many types of cancer. When the level of SUPT20HL1 is increased, it can stimulate the immune system to attack the cancer cells.

One of the potential benefits of targetingSUPT20HL1 is that it can be used to treat cancer without causing harm to healthy cells. This is becauseSUPT20HL1 is primarily expressed in immune cells, and drugs that target this protein are unlikely to have any impact on non-immune cells.

Another potential benefit of targetingSUPT20HL1 is that it can be used to treat multiple types of cancer. BecauseSUPT20HL1 is overexpressed in many types of cancer, it could be a useful target for treatments that target this protein, regardless of the specific type of cancer.

In addition to its potential as a cancer treatment,SUPT20HL1 is also a potential biomarker for the disease. This is because the level of this protein can be easily measured and correlated with the level of cancer-related markers in the body. This makes it a promising tool for the development of new cancer diagnostic tests.

SUPT20HL1 is also a potential target for drug development because it is involved in the immune response. This means that drugs that target this protein could be used to treat autoimmune diseases, as well as cancer.

Overall,SUPT20HL1 is a promising drug target and biomarker for the treatment of cancer and other diseases. Further research is needed to fully understand its potential and to develop effective treatments.

Protein Name: SUPT20H Like 1

More Common Targets